Episode 3.3 When should we use new treatments? Jada and cfDNA

In this episode we discuss the new Jada postpartum hemorrhage device. More importantly, we discuss the process for choosing to utilize new interventions in clinical practice. Then we discuss a recent New York Times article detailing the problem of false positives in the noninvasive prenatal screening tests. 

Links Discussed:

For A New Device To Treat Maternal Bleeding, A Young Entrepreneur’s Big Step Was Passing The Torch

Intrauterine Vacuum-Induced Hemorrhage-Control Device for Rapid Treatment of Postpartum Hemorrhage

Merck Buys Alydia

When Evidence Says No, But Doctors Say Yes

Device Makers Have Funneled Billions to Orthopedic Surgeons Who Use Their Products

Search Open Payments

Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation

I Investigated the Prenatal Testing Industry

When They Warn of Rare Disorders, These Prenatal Tests Are Usually Wrong